CLINICAL TRIALS PROFILE FOR LOPINAVIR; RITONAVIR

505(b)(2) Clinical Trials for Lopinavir; Ritonavir

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00196625 ↗	Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.	Completed	French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	2000-11-01	HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.

All Clinical Trials for Lopinavir; Ritonavir

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004578 ↗	ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects	Completed	Abbott	Phase 1/Phase 2	1997-11-01	To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
NCT00006144 ↗	A Study of HIV-Disease Development in Aging	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2000-10-01	The purpose of this study is to better understand the relationship between age and HIV disease progression. This study will explore the possible relationship between age and HIV disease progression. Older age is an important risk factor for faster disease development, but older people may respond better to combination drug therapy. This relationship needs to be understood better.
NCT00014937 ↗	Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	ACTG 388 was a clinical trial that compared three- and four-drug anti-HIV drug regimens and demonstrated the effectiveness of a three-drug regimen. This study will compare the ability of two different three-drug anti-HIV drug regimens to reduce levels of HIV in the blood. The study will also evaluate whether patients discontinue the regimens because of drug side effects.
NCT00017992 ↗	Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV	Unknown status	Triangle Pharmaceuticals	Phase 2	1969-12-31	The purpose of this study is to see if emtricitabine is safe in children infected with HIV and to determine the best dose.
NCT00023218 ↗	Effect of a Change in HIV Therapy on Liver Steatosis, Inflammation, and Fibrosis	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)	N/A	1969-12-31	The purpose of this study is to look at how 2 different anti-HIV drug treatments affect the liver. The use of anti-HIV drugs like the nucleoside reverse transcriptase inhibitors (NRTIs) may be linked to liver problems like fatty changes, scarring, abnormal liver function tests (LFTs), and lactic acidemia (an increase in lactic acid in the blood). Increased liver enzymes may mean liver damage. The way that the liver changes in people with abnormal LFTs and lactic acidemia is not completely understood.
NCT00025727 ↗	Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure	Unknown status	GlaxoSmithKline	Phase 3	2001-05-01	The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.

Clinical Trial Conditions for Lopinavir; Ritonavir

Condition Name

Condition Name for Lopinavir; Ritonavir
Intervention	Trials
HIV Infections	139
COVID-19	36
HIV	35
HIV Infection	32

Condition MeSH

Condition MeSH for Lopinavir; Ritonavir
Intervention	Trials
HIV Infections	195
COVID-19	69
Acquired Immunodeficiency Syndrome	44
Infections	37

Clinical Trial Locations for Lopinavir; Ritonavir

Trials by Country

Trials by Country for Lopinavir; Ritonavir
Location	Trials
United States	756
Spain	88
Thailand	66
Canada	56
South Africa	54

Trials by US State

Trials by US State for Lopinavir; Ritonavir
Location	Trials
California	61
New York	55
Florida	42
Texas	40
Illinois	40

Clinical Trial Progress for Lopinavir; Ritonavir

Clinical Trial Phase

Clinical Trial Phase for Lopinavir; Ritonavir
Clinical Trial Phase	Trials
Phase 4	90
Phase 3	76
Phase 2/Phase 3	24

Clinical Trial Status

Clinical Trial Status for Lopinavir; Ritonavir
Clinical Trial Phase	Trials
Completed	219
Terminated	30
Recruiting	30

Clinical Trial Sponsors for Lopinavir; Ritonavir

Sponsor Name

Sponsor Name for Lopinavir; Ritonavir
Sponsor	Trials
Abbott	55
National Institute of Allergy and Infectious Diseases (NIAID)	52
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	20

Sponsor Type

Sponsor Type for Lopinavir; Ritonavir
Sponsor	Trials
Other	504
Industry	147
NIH	87